Evidence for cortical inhibitory and excitatory dysfunction in obsessive compulsive disorder

Neuropsychopharmacology

Volumn 37, Issue 5, 2012, Pages 1144-1151

  Richter, Margaret A ^a   De Jesus, Danilo R ^b   Hoppenbrouwers, Sylco ^c   Daigle, Melissa ^b   Deluce, Jasna ^a   Ravindran, Lakshmi N ^b   Fitzgerald, Paul B ^d   Daskalakis, Zafiris J ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UTRECHT UNIVERSITY   (Netherlands)

^d MONASH UNIVERSITY   (Australia)

Author keywords

cortical; GABA; inhibition; OCD; physiology; TMS

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GABAERGIC SYSTEM; HUMAN; MAJOR DEPRESSION; MALE; NERVOUS SYSTEM FUNCTION; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RECEPTOR GENE; TRANSCRANIAL MAGNETIC STIMULATION;

ADULT; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORTICAL SPREADING DEPRESSION; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR CORTEX; OBSESSIVE-COMPULSIVE DISORDER; PERSONALITY INVENTORY; PSYCHIATRIC STATUS RATING SCALES; TIME FACTORS; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 84858339548     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2011.300     Document Type: Article

References (65)

1. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA (2004). Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: A preliminary study. Psychopharmacology (Berl) 174: 530-538.
2. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL (2006). Glutamate transporter gene SLC1A1 associated with obsessivecompulsive disorder. Arch Gen Psychiatry 63: 769-776.
3. Baxter Jr LR, Schwartz JM, Phelps ME, Mazziotta JC, Guze BH, Selin CE et al (1989). Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch Gen Psychiatry 46: 243-250.
4. Beck AT, Beamesderfer A (1974). Assessment of depression: The depression inventory. Mod Probl Pharmacopsychiatry 7: 151-169.
5. Cantello R, Gianelli M, Civardi C, Mutani R (1992). Magnetic brain stimulation: The silent period after the motor evoked potential. Neurology 42: 1951-1959.
6. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ (2005). The neuropsychology of obsessive compulsive disorder: The importance of failures in cognitive and behavioural inhibition as candidate endophenotypic markers. Neurosci Biobehav Rev 29: 399-419.
7. Chen R, Samii A, Canos M, Wassermann EM, Hallett M (1997). Effects of phenytoin on cortical excitability in humans. Neurology 49: 881-883.
8. Daskalakis ZJ, Christensen BK, Chen R, Fitzgerald PB, Zipursky RB, Kapur S (2002a). Evidence for impaired cortical inhibition in schizophrenia using transcranial magnetic stimulation. Arch Gen Psychiatry 59: 347-354.
9. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Chen R (2002b). Transcranial magnetic stimulation: A new investigational and treatment tool in psychiatry. J Neuropsychiatry Clin Neurosci 14: 406-415.
10. Daskalakis ZJ, Christensen BK, Fitzgerald PB, Moller B, Fountain SI, Chen R (2008a). Increased cortical inhibition in persons with schizophrenia treated with clozapine. J Psychopharmacol 22: 203-209.
11. Daskalakis ZJ, Farzan F, Barr MS, Rusjan PM, Favalli G, Levinson AJ et al (2008b). Evaluating the relationship between long interval cortical inhibition, working memory and gamma band activity in the dorsolateral prefrontal cortex. Clin EEG Neurosci 39: 150-155.
12. Daskalakis ZJ, Molnar GF, Christensen BK, Sailer A, Fitzgerald PB, Chen R (2003). An automated method to determine the transcranial magnetic stimulation-induced contralateral silent period. Clin Neurophysiol 114: 938-944.
13. Davies CH, Davies SN, Collingridge GL (1990). Paired-pulse depression of monosynaptic GABA-mediated inhibitory postsynaptic responses in rat hippocampus. J Physiol 424: 513-531.
14. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M et al (2006). Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. Arch Gen Psychiatry 63: 778-785.
15. Fitzgerald PB, Brown TL, Daskalakis ZJ, Kulkarni J (2002). A transcranial magnetic stimulation study of inhibitory deficits in the motor cortex in patients with schizophrenia. Psychiatry Res 114: 11-22.
16. Fuhr P, Agostino R, Hallett M (1991). Spinal motor neuron excitability during the silent period after cortical stimulation. Electroencephalogr Clin Neurophysiol 81: 257-262.
17. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR et al (1989a). The Yale-Brown Obsessive Compulsive Scale. II. Validity. Arch Gen Psychiatry 46: 1012-1016.
18. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL et al (1989b). The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Arch Gen Psychiatry 46: 1006-1011.
19. Graybiel AM, Rauch SL (2000). Toward a neurobiology of obsessive-compulsive disorder. Neuron 28: 343-347.
20. Greenberg BD, Gabriels LA, Malone Jr DA, Rezai AR, Friehs GM, Okun MS et al (2010). Deep brain stimulation of the ventral internal capsule/ventral striatum for obsessive-compulsive disorder: Worldwide experience. Mol Psychiatry 15: 64-79.
21. Greenberg BD, Ziemann U, Cora-Locatelli G, Harmon A, Murphy DL, Keel JC et al (2000). Altered cortical excitability in obsessivecompulsive disorder. Neurology 54: 142-147.
22. Greenberg BD, Ziemann U, Harmon A, Murphy DL, Wassermann EM (1998). Decreased neuronal inhibition in cerebral cortex in obsessive-compulsive disorder on transcranial magnetic stimulation. Lancet 352: 881-882.
23. Karno M, Golding JM, Sorenson SB, Burnam MA (1988). The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 45: 1094-1099.
24. Koran LM, Thienemann ML, Davenport R (1996). Quality of life for patients with obsessive-compulsive disorder. Am J Psychiatry 153: 783-788.
25. Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A et al (1993). Corticocortical inhibition in human motor cortex. J Physiol 471: 501-519.
26. Lefaucheur JP, Lucas B, Andraud F, Hogrel JY, Bellivier F, Del Cul A et al (2008). Inter-hemispheric asymmetry of motor corticospinal excitability in major depression studied by transcranial magnetic stimulation. J Psychiatr Res 42: 389-398.
27. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ (2010). Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 67: 458-464.
28. Levinson AJ, Young LT, Fitzgerald PB, Daskalakis ZJ (2007). Cortical inhibitory dysfunction in bipolar disorder: A study using transcranial magnetic stimulation. J Clin Psychopharmacol 27: 493-497.
29. Liang KY, Wang Y, Shugart YY, Grados M, Fyer AJ, Rauch S et al (2008). Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding. Am J Med Genet B Neuropsychiatr Genet 147B: 1000-1002.
30. Liepert J, Schwenkreis P, Tegenthoff M, Malin JP (1997). The glutamate antagonist riluzole suppresses intracortical facilitation. J Neural Transm 104: 1207-1214.
31. Liu SK, Fitzgerald PB, Daigle M, Chen R, Daskalakis ZJ (2009). The relationship between cortical inhibition, antipsychotic treatment, and the symptoms of schizophrenia. Biol Psychiatry 65: 503-509.
32. Maltby N, Tolin DF, Worhunsky P, O'Keefe TM, Kiehl KA (2005). Dysfunctional action monitoring hyperactivates frontal-striatal circuits in obsessive-compulsive disorder: An event-related fMRI study. Neuroimage 24: 495-503.
33. Minelli A, Bortolomasi M, Scassellati C, Salvoro B, Avesani M, Manganotti P (2010). Effects of intravenous antidepressant drugs on the excitability of human motor cortex: A study with paired magnetic stimulation on depressed patients. Brain Stimul 3: 15-21.
34. Morey LC (1991). Personality Assessment InventoryFProfessional Manual. Psychological Assessment Resources: Florida.
35. Morey LC (1996). An interpretive Guide to the Personality Assessment Inventory (PAI). Psychological Assessment Resources: Florida.
36. Page LA, Rubia K, Deeley Q, Daly E, Toal F, Mataix-Cols D et al (2009). A functional magnetic resonance imaging study of inhibitory control in obsessive-compulsive disorder. Psychiatry Res 174: 202-209.
37. Paulus W, Classen J, Cohen LG, Large CH, Di Lazzaro V, Nitsche M et al (2008). State of the art: Pharmacologic effects on cortical excitability measures tested by transcranial magnetic stimulation. Brain Stimul 1: 151-163.
38. Rauch SL, Savage CR (1997). Neuroimaging and neuropsychology of the striatum. Bridging basic science and clinical practice. Psychiatr Clin North Am 20: 741-768.
39. Richter MA, Summerfeldt LJ, Antony MM, Swinson RP (2003). Obsessive-compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders. Depress Anxiety 18: 118-127.
40. Robol E, Fiaschi A, Manganotti P (2004). Effects of citalopram on the excitability of the human motor cortex: A paired magnetic stimulation study. J Neurol Sci 221: 41-46.
41. Roick H, von Giesen HJ, Benecke R (1993). On the origin of the postexcitatory inhibition seen after transcranial magnetic brain stimulation in awake human subjects. Exp Brain Res 94: 489-498.
42. Rosenberg DR, Keshavan MS (1998). A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 43: 623-640.
43. Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ (2000). Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry 39: 1096-1103.
44. Rossi S, Bartalini S, Ulivelli M, Mantovani A, Di Muro A, Goracci A et al (2005). Hypofunctioning of sensory gating mechanisms in patients with obsessive-compulsive disorder. Biol Psychiatry 57: 16-20.
45. Rotge JY, Guehl D, Dilharreguy B, Tignol J, Bioulac B, Allard M et al (2009). Meta-analysis of brain volume changes in obsessivecompulsive disorder. Biol Psychiatry 65: 75-83.
46. Ruscio AM, Stein DJ, Chiu WT, Kessler RC (2010). The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. Mol Psychiatry 15: 53-63.
47. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM et al (2001). Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry 50: 159-170.
48. Saxena S, Brody AL, Schwartz JM, Baxter LR (1998). Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. Br J Psychiatry Suppl 35: 26-37.
49. Schwenkreis P, Witscher K, Janssen F, Addo A, Dertwinkel R, Zenz M et al (1999). Influence of the N-methyl-D-aspartate antagonist memantine on human motor cortex excitability. Neurosci Lett 270: 137-140.
50. Siebner HR, Dressnandt J, Auer C, Conrad B (1998). Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 21: 1209-1212.
51. Stewart SE, Rosario MC, Brown TA, Carter AS, Leckman JF, Sukhodolsky D et al (2007). Principal components analysis of obsessive-compulsive disorder symptoms in children and adolescents. Biol Psychiatry 61: 285-291.
52. Summerfeldt LJ, Richter MA, Antony MM, Swinson RP (1999). Symptom structure in obsessive-compulsive disorder: A confirmatory factor-analytic study. Behav Res Ther 37: 297-311.
53. Tergau F, Wanschura V, Canelo M, Wischer S, Wassermann EM, Ziemann U et al (1999). Complete suppression of voluntary motor drive during the silent period after transcranial magnetic stimulation. Exp Brain Res 124: 447-454.
54. van den Heuvel OA, Veltman DJ, Groenewegen HJ, Cath DC, van Balkom AJ, van Hartskamp J et al (2005). Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. Arch Gen Psychiatry 62: 301-309.
55. Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Lee CK et al (1994). The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 55(Suppl): 5-10.
56. Werhahn KJ, Kunesch E, Noachtar S, Benecke R, Classen J (1999). Differential effects on motorcortical inhibition induced by blockade of GABA uptake in humans. J Physiol 517(Part 2): 591-597.
57. Whiteside SP, Port JD, Abramowitz JS (2004). A meta-analysis of functional neuroimaging in obsessive-compulsive disorder. Psychiatry Res 132: 69-79.
58. Woolley J, Heyman I, Brammer M, Frampton I, McGuire PK, Rubia K (2008). Brain activation in paediatric obsessive compulsive disorder during tasks of inhibitory control. Br J Psychiatry 192: 25-31.
59. Yucel M, Harrison BJ, Wood SJ, Fornito A, Wellard RM, Pujol J et al (2007). Functional and biochemical alterations of the medial frontal cortex in obsessive-compulsive disorder. Arch Gen Psychiatry 64: 946-955.
60. Zai G, Arnold P, Burroughs E, Barr CL, Richter MA, Kennedy JL (2005). Evidence for the gamma-amino-butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessivecompulsive disorder. Am J Med Genet B Neuropsychiatr Genet 134B: 25-29.
61. Ziemann U, Chen R, Cohen LG, Hallett M (1998). Dextromethorphan decreases the excitability of the human motor cortex. Neurology 51: 1320-1324.
62. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W (1996a). The effect of lorazepam on the motor cortical excitability in man. Exp Brain Res 109: 127-135.
63. Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W (1996b). Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study. Ann Neurol 40: 367-378.
64. Ziemann U, Paulus W, Rothenberger A (1997a). Decreased motor inhibition in Tourette's disorder: Evidence from transcranial magnetic stimulation. Am J Psychiatry 154: 1277-1284.
65. Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W (1997b). Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr Clin Neurophysiol 105: 430-437.